The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma

Eitemau Tebyg

• Effects of epidermal growth factor receptor‐tyrosine kinase inhibitors alone on EGFR‐mutant non‐small cell lung cancer with brain metastasis
  gan: Zhang, Qiuyi, et al.
  Cyhoeddwyd: (2016)
• Plasma T790M and HGF as potential predictive markers for EGFR-TKI re-challenge
  gan: Nakamura, Tomomi, et al.
  Cyhoeddwyd: (2017)
• The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
  gan: Tseng, Jeng-Sen, et al.
  Cyhoeddwyd: (2016)
• Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
  gan: Kejing Tang, et al.
  Cyhoeddwyd: (2019-02-01)
• Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
  gan: Tang, Kejing, et al.
  Cyhoeddwyd: (2018)